Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

1117 - Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine.

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Presenters

Shigetaka Suekane

Citation

Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239

Authors

S. Suekane1, M. Noguchi2, M. Terasaki2, S. Yutani2, Y. Narita3, A. Yamada4, S. Shichijo2, T. Igawa1, K. Itoh2

Author affiliations

  • 1 Urology, Kurume University School of Medicine, 830-0011 - Kurume/JP
  • 2 Cancer Vaccine Center, Kurume University School of Medicine, 839-0863 - Kurume/JP
  • 3 Neurosurgery And Neuro-oncology, National cancer center hospital, 104-0045 - Tokyo/JP
  • 4 Research Center For Innovative Cancer Therapy, Kurume University, 830-0011 - Kurume/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1117

Background

To determine biomarkers predictive of overall survival (OS) in advanced cancer patients treated with a peptide-based cancer vaccine.

Methods

The samples from two randomized, double-blind, placebo-controlled, phase III trials of personalized peptide vaccine (PPV) for advanced prostate cancer patients (n = 306) and recurrent glioblastoma (n = 88) patients, those from one single arm phase II trial of PPV for various types of advanced cancer patients (n = 2588), and those from one randomized placebo-controlled non-personalized phase II trial (n = 51) were provided for this retrospective biomarker study.

Results

No significant differences in clinical benefit (overall survival, OS) were found between the patients receiving PPV and those receiving placebo in each of the two randomized, double-blind, placebo-controlled, phase III trials. The neutrophil or lymphocyte proportion in advanced prostate cancer patients prior to study entry was a biomarker discriminating the PPV patients (70%) who showed significantly shorter OS relative to placebo patients from the remaining PPV patients who showed significantly longer OS relative to placebo patients. The CCL2 level prior to the study entry in recurrent glioblastoma patients was the other biomarker discriminating the PPV patients (40%) who showed significantly shorter OS relative to placebo patients from the remaining PPV patients who showed significantly longer OS relative to placebo patients. The neutrophil or lymphocyte proportion prior to study entry was also a biomarker discriminating the PPV patients (60%) with significantly shorter OS from the remaining PPV patients entered in the single arm phase II study in all the advanced cancer patients other than gastric cancer or glioblastoma patients. This marker could also discriminate patients who showed significantly shorter OS from the remaining patients in the non-personalized peptide vaccine phase II study for prostate cancer patients.

Conclusions

Peptide-based cancer vaccine shortened the OS of a large portion, but not all, of advanced cancer patients with various types of cancer. Prospective clinical studies of peptide-based cancer vaccines using the newly defined prognostic markers may be warranted.

Clinical trial identification

UMIN Clinical Trials Registry, 6970, 113088, 11028, 1482, 1839, 1844, 1847, 1850, 1854, 1855, 1856, 1875, 1881, 1882, 1883, 1884, 2282, 3590, 5631, 6249, 6295, 6493, 7493, 8126, 8823, 8824, 8825, 8826, 8827, 8828, 10068, 19390, 2906, 2907, 2908, 2984, 2985, 2987, 3027, 3028, 3029, 3059, 3060, 3081, 3082, 3083, 5329, 10290, 11593, 14855, 19802, 19879, 6927,11230.

Editorial acknowledgement

Legal entity responsible for the study

President Kyogo Itoh,M.D., Ph.D., Cancer vaccine center, Kurume University School of Medicine, Japan.

Funding

Grants from the Japan Agency for Medical Research and Development (16ck0106086h0003, 18im0110802h0008), the Ministry of Health, Labor and Welfare of Japan, and FUJIFILM Corporation.

Disclosure

M. Noguchi: Advisory / Consultancy: BrightPath Biotherapeutics Co. Ltd. A. Yamada: Advisory / Consultancy: BrightPath Biotherapeutics Co. Ltd. K. Itoh: Advisory / Consultancy, Research grant / Funding (self): Taiho Pharmaceutical Company. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.